The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions - Scorecard - MDSpire

The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions

  • By

  • Yiying Liu

  • Ruikang Liu

  • Kai Yang

  • Jun Li

  • Guancheng Ye

  • Xuanchun Huang

  • Shiyi Tao

  • Tiantian Xue

  • Yulian Yuan

  • May 21, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy and Safety of Oral Chinese Patent Medicines for Myocardial Infarction with Heart Failure: A Network Meta-Analysis of Twelve Treatment Approaches

At a Glance

CategoryDetail
ConditionMyocardial Infarction with Heart Failure (MI-HF)
Key MechanismsImprovement of cardiac function, ventricular remodeling, and exercise tolerance
Target PopulationPatients with myocardial infarction complicated by heart failure
Care SettingClinical settings utilizing Traditional Chinese Medicine alongside conventional treatment

Key Highlights

  • Yixinshu capsules showed the best overall therapeutic effect.
  • Xintong oral liquid improved LVEF and reduced LVESD most effectively.
  • Shexiang Baoxin pill was optimal for reducing LVEDD.
  • Guanxin Shutong capsules effectively lowered NT-proBNP and increased 6 MWT distance.
  • Oral CPMs combined with CT significantly enhance cardiac function and quality of life.

Guideline-Based Recommendations

Diagnosis

  • Early identification of patients at risk for cardiogenic shock is crucial.

Management

  • Integrate oral Chinese patent medicines with conventional treatment for improved outcomes.

Monitoring & Follow-up

  • Monitor cardiac function and symptoms regularly in MI-HF patients.

Risks

  • Short-term tolerability is favorable, but safety conclusions are limited due to poor reporting.

Patient & Prescribing Data

Patients diagnosed with myocardial infarction and heart failure

Oral CPMs demonstrate considerable potential in improving cardiac function and alleviating symptoms.

Clinical Best Practices

  • Utilize network Meta-analysis for evidence-based selection of CPMs.
  • Consider patient-specific factors when integrating CPMs with conventional treatments.
  • Regularly assess the effectiveness and safety of prescribed CPMs.

Related Resources & Content

Original Source(s)

The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions

  • by Yiying Liu, Ruikang Liu, Kai Yang, Jun Li, Guancheng Ye, Xuanchun Huang, Shiyi Tao, Tiantian Xue, Yulian Yuan

  • May 21, 2026

Related Content

Longitudinal assessment of myocardial involvement in PASC-CVS: a single-center study from China based on multiparametric CMR

Complete revascularization and heart failure risk in acute coronary syndrome across the ejection fraction spectrum: focus on LVEF-dependent effects

Correction: Multicriteria Optimization of Language Models for Heart Failure With Preserved Ejection Fraction Symptom Detection in Spanish Electronic Health Records: Comparative Modeling Study